UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 24, 2010

Emergent BioSolutions Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)		001-33137 (Commission File Number)		14-1902018 (IRS Employer Identification No.)

2273 Research Boulevard, Suite 400, Rockville, Maryland (Address of Principal Executive Offices)		20850 (Zip Code)

Registrant’s telephone number, including area code: (301) 795-1800

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.02.		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 24, 2010, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed John E. Niederhuber, M.D. as a Class III director. Dr. Niederhuber is an independent director within the meaning of the rules of the New York Stock Exchange. Dr. Niederhuber will stand for election with the Company’s other Class III directors at the Company’s 2012 annual meeting of stockholders.

Dr. Niederhuber joined Inova Health System in August 2010 as Executive Vice President and CEO of the Inova Institute for Translational Research and Personalized Medicine. Dr. Niederhuber also has served as an adjunct investigator at the Center for Cancer Research at the National Cancer Institute, or NCI, since August 2010. From 2005 to July 2010, Dr. Niederhuber served as director of NCI. Prior to his service with NCI, Dr. Niederhuber was Director of the University of Wisconsin Comprehensive Cancer Center and a professor of surgery and oncology (member of the McArdle Laboratory) at the University of Wisconsin School of Medicine. He also chaired the Department of Surgery at Stanford University and held professorships at the Johns Hopkins University School of Medicine and at the University of Michigan. Dr. Niederhuber is a graduate of Bethany College in West Virginia and the Ohio State University School of Medicine. He trained in surgery at the University of Michigan.

There is no arrangement or understanding pursuant to which Dr. Niederhuber was appointed as a director and there are no related party transactions between the Company and Dr. Niederhuber.

On August 24, 2010, the Company issued a news release on Dr. Niederhuber’s appointment to the Board, which is furnished as Exhibit 99.1 and is attached to this Form 8-K.

Item 9.01.		Financial Statements and Exhibits.

	99.1			Press Release dated August 24, 2010

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INDEX TO EXHIBITS

Exhibit No.				Description
	99.1			Press Release dated August 24, 2010

Exhibit 99.1

FOR IMMEDIATE RELEASE

Investor Contact
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com

Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com

EMERGENT BIOSOLUTIONS ANNOUNCES APPOINTMENT OF JOHN E. NIEDERHUBER, M.D. TO THE COMPANY’S BOARD OF DIRECTORS

ROCKVILLE, MD, ROCKVILLE, Md., Aug 24, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s Board of Directors appointed John E. Niederhuber, M.D. as a Class III Director for a two-year term that will expire at the 2012 annual meeting of stockholders.

“Dr. Niederhuber is a nationally renowned surgeon and researcher who has dedicated his four-decade career to the treatment and study of cancer. As we expand our portfolio to include cancer therapeutics, his oncology research and clinical experience will be an invaluable asset in guiding Emergent’s management team towards further growth and in increasing value for shareholders,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “We are delighted to welcome him to Emergent's Board of Directors.”

“I am pleased to serve on the Board of a company that has a strong interest in providing new treatments to cancer patients. Their mission in vaccine development to protect life aligns closely with my goals to find life-saving treatments that can benefit patients worldwide,” said Dr. Niederhuber. “I look forward to the opportunity to contribute to Emergent’s success.”

From 2005 to 2010, Dr. Niederhuber served as the director of the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), one of the largest medical research institutes in the world. As NCI director, Dr. Niederhuber’s accomplishments include advancing drug and technology innovation and technology infrastructure, bringing cancer science to patients through community cancer centers, and working to reduce the inequities of cancer care. Recently, Dr. Niederhuber joined Inova Health System as Executive Vice President and CEO of the Inova Institute for Translational Research and Personalized Medicine. Dr. Niederhuber is also an adjunct investigator at NCI’s Center for Cancer Research. His research focuses on factors in the tumor microenvironment, in particular on cancer activated fibroblasts (CAFs) that lead to increased malignancy. As a surgeon, Dr. Niederhuber’s clinical focus has been on gastrointestinal cancer, hepatobiliary (liver, bile duct, and gallbladder) cancer, pancreatic cancer and breast cancer. Prior to coming to NCI, Dr. Niederhuber was Director of the University of Wisconsin Comprehensive Cancer Center and a professor of surgery and oncology (member of the McArdle Laboratory) at the University of Wisconsin School of Medicine. Earlier in his career, he chaired the Department of Surgery at Stanford University and held professorships at the Johns Hopkins University School of Medicine and at the University of Michigan.

Dr. Niederhuber is a graduate of Bethany College in West Virginia and the Ohio State University School of Medicine. He trained in surgery at the University of Michigan.

About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax^® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.